Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.41 |
| ▸ | ESR1 | P03372 | 8/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ESRRB | O95718 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232518 | 1.00 | NR3C1 (0.41) | NR3C1ESR1ESR2PGRHSD17B10 | |
| SCHEMBL6232522 | 1.00 | NR3C1 (0.41) | NR3C1ESR1ESR2PGRHSD17B10 | |
| SCHEMBL6233085 | 0.89 | NR3C1 (0.41) | NR3C1ESR1ESR2PGRHSD17B10 | |
| SCHEMBL4587414 | 0.89 | NR3C1 (0.41) | NR3C1ESR1ESR2PGRHSD17B10 | |
| SCHEMBL6233082 | 0.89 | NR3C1 (0.41) | NR3C1ESR1ESR2PGRHSD17B10 | |
| SCHEMBL4587411 | 0.89 | NR3C1 (0.41) | NR3C1ESR1ESR2PGRHSD17B10 | |
| SCHEMBL4588729 | 0.88 | NR3C1 (0.52) | NR3C1ESR1ESR2PGRHSD17B10 | |
| SCHEMBL2215608 | 0.87 | NR3C1 (0.40) | NR3C1ESR1ESR2PGRHSD17B10 | |
| SCHEMBL4589641 | 0.86 | LMNA (0.39) | ESR1HSD17B10LMNATSHRCYP2C9 | |
| SCHEMBL4587939 | 0.85 | NR3C1 (0.41) | NR3C1ESR1ESR2PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282340-A1 | DRUG DELIVERY SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-11-08 | — | — | US | claimed |
| EP-2358351-A1 | DRUG DELIVERY SYSTEM | Bayer Pharma Aktiengesellschaft (DE) | 2011-08-24 | — | — | EP | claimed |
| US-20110178052-A1 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-21 | — | — | US | claimed |
| EP-2252261-A2 | DRUG DELIVERY SYSTEM WITH STABILISING EFFECT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-11-24 | — | — | EP | claimed |
| WO-2010057594-A1 | DRUG DELIVERY SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-27 | — | — | WO | claimed |
| EP-2143432-A1 | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer | Bayer Schering Pharma AG (DE) | 2010-01-13 | — | — | EP | claimed |
| WO-2009100871-A2 | DRUG DELIVERY SYSTEM WITH STABILISING EFFECT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-20 | — | — | WO | claimed |
| US-7414043-B2 | 9-α-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2008-08-19 | — | — | US | claimed |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | KOSEMUND DIRK | 2008-06-05 | — | — | US | claimed |
| EP-1517914-B1 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AG (DE) | 2005-08-31 | — | — | EP | claimed |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | claimed |
| US-20120282340-A1 | DRUG DELIVERY SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-11-08 | — | — | US | disclosed |
| EP-2358351-A1 | DRUG DELIVERY SYSTEM | Bayer Pharma Aktiengesellschaft (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-20110178052-A1 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-21 | — | — | US | disclosed |
| EP-2318009-A1 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER | Bayer Schering Pharma AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1517914-B1 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1517914-A2 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | Schering Aktiengesellschaft (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | disclosed |
| WO-2003104253-A2 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | ESRRA, ESR2, ESR1 | NR3C1 122/4885ESR1 3/4885ESR2 2/4885 |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | CYP19A1, ESR2, HSD17B11 | NR3C1 52/4885ESR1 7/4885ESR2 2/4885 |
| US-20110178052-A1 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER | ESR2, ESRRA, ESRRG | NR3C1 119/4885ESR1 5/4885ESR2 1/4885 |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | ESRRA, ESR2, HSD17B11 | NR3C1 137/4885ESR1 7/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.